MRKMerck & Co., Inc.

NYSE merck.com


$ 113.80 $ 0.69 (0.61 %)    

Thursday, 01-Aug-2024 15:59:58 EDT
QQQ $ 457.29 $ -11.41 (-2.42 %)
DIA $ 403.27 $ -5.26 (-1.29 %)
SPY $ 541.71 $ -7.80 (-1.42 %)
TLT $ 95.61 $ 0.50 (0.53 %)
GLD $ 225.83 $ -0.78 (-0.34 %)
$ 113.82
$ 112.30 x 100
$ 113.80 x 100
-- - --
$ 97.23 - $ 134.63
14,117,458
na
288.28B
$ 0.33
$ 125.01
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-03-2024 03-31-2024 10-Q
2 02-26-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-05-2023 03-31-2023 10-Q
6 02-24-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-25-2022 12-31-2021 10-K
11 11-05-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 02-25-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-08-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-07-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 02-27-2018 12-31-2017 10-K
27 11-07-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 02-28-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-08-2016 06-30-2016 10-Q
33 05-09-2016 03-31-2016 10-Q
34 02-26-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-27-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-merck--co-lowers-price-target-to-142

Barclays analyst Carter Gould maintains Merck & Co (NYSE:MRK) with a Overweight and lowers the price target from $145 to...

 b-of-a-securities-maintains-buy-on-merck--co-lowers-price-target-to-145

B of A Securities analyst Geoff Meacham maintains Merck & Co (NYSE:MRK) with a Buy and lowers the price target from $150...

 wells-fargo-maintains-equal-weight-on-merck--co-lowers-price-target-to-125

Wells Fargo analyst Mohit Bansal maintains Merck & Co (NYSE:MRK) with a Equal-Weight and lowers the price target from $1...

 ubs-maintains-buy-on-merck--co-lowers-price-target-to-142

UBS analyst Colin Bristow maintains Merck & Co (NYSE:MRK) with a Buy and lowers the price target from $148 to $142.

 nasdaq-tumbles-as-microsoft-nvidia-and-other-tech-stocks-decline-greed-index-moves-to-fear-zone

Market sentiment declines as Fear & Greed index moves to 'Fear' zone. Dow Jones gains ahead of major earnings and F...

 bristol-myers-johnson--johnson-abbvie-astrazeneca-expect-minimal-impact-from-upcoming-medicare-price-negotiations

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact fro...

 tech-stocks-drop-ahead-of-key-earnings-nvidia-falls-crowdstrike-hits-8-month-low-whats-driving-markets-tuesday

Investor sentiment took a hit on Tuesday as caution prevailed ahead of significant market events, including key tech earnings r...

 pfizer-records-first-sales-growth-in-its-post-covid-era-and-it-owes-it-to-cancer

The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild th...

 merck-exec-says-targeting-next-years-rsv-season-in-us-for-rsv-antibody

- Conf Call

Core News & Articles

- Conf. Call

 mercks-q2-earnings-revenue-and-eps-beat-helped-by-strong-keytruda-sales-but-acquisition-costs-bites-into-annual-profit-forecast

Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION